These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 35141944)

  • 1. Ensuring robustness in the quality of antibiotic susceptibility test discs for four novel antibiotics.
    Ahirrao VK; Jadhav RA; Vaidya SN; Bhagwat SS; Yeole RD; Patel MV
    Biomed Chromatogr; 2022 Jun; 36(6):e5354. PubMed ID: 35141944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
    Gill CM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lasko MJ; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Evaluation of the
    Mullane EM; Avery LM; Nicolau DP
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy.
    Barceló I; Cabot G; Palwe S; Joshi P; Takalkar S; Periasamy H; Cortés-Lara S; Zamorano L; Sánchez-Diener I; Moya B; Bhagwat S; Patel M; Oliver A
    J Antimicrob Chemother; 2021 Sep; 76(10):2546-2557. PubMed ID: 34219168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.
    Moya B; Bhagwat S; Cabot G; Bou G; Patel M; Oliver A
    J Antimicrob Chemother; 2020 Jun; 75(6):1474-1478. PubMed ID: 32083659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
    Khan Z; Iregui A; Landman D; Quale J
    J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Monogue ML; Tabor-Rennie J; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.
    Avery LM; Mullane EM; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105863. PubMed ID: 31870597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
    Sader HS; Carvalhaes CG; Mendes RE; Castanheira M
    Int J Infect Dis; 2022 Mar; 116():306-312. PubMed ID: 35066163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
    Rodvold KA; Gotfried MH; Chugh R; Gupta M; Patel A; Chavan R; Yeole R; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
    Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
    Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Susceptibility Profiles To Predict the Presence of Carbapenemase Genes among Carbapenem-Resistant Pseudomonas aeruginosa Isolates.
    Vallabhaneni S; Huang JY; Grass JE; Bhatnagar A; Sabour S; Lutgring JD; Campbell D; Karlsson M; Kallen AJ; Nazarian E; Snavely EA; Morris S; Wang C; Lee R; Koag M; Lewis R; Garcia B; ; Brown AC; Walters MS
    J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33762362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.